Surrogate Markers in Clinical Studies: Problems Solved or Created?

Braden Manns, William F. Owen, Wolfgang C. Winkelmayer, P.J. Devereaux, Marcello Tonelli

Type: Editorial

Publication Date: 2006-06-21

Citations: 44

DOI: https://doi.org/10.1053/j.ajkd.2006.03.044

View Publication

Download PDF

Locations

American Journal of Kidney Diseases - View - PDF
PubMed - View

Similar Works

Action	Title	Year	Authors
+	The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?	2012	David L. DeMets
+	Surrogate endpoints: do they really contribute in therapeutic decision making?	1999	Ray K Sarkar Pk
+	Surrogate outcome markers in research and clinical practice	2009	Scott Twaddell
+	Surrogate endpoints: a key concept in clinical epidemiology	2023	Robin Christensen Oriana Ciani Anthony Muchai Manyara Rod S Taylor
+	Challenge of Surrogate Endpoints	2012	James L. Furgerson William N. Hannah J. C. Thompson
+	Surrogate measures in clinical trials	1990
+ PDF Chat	Biomarkers and surrogate endpoints	2005	Jeffrey K Aronson
+	The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases	2001	Eva Lonn
+	Surrogate end points and their role in clinical trial	2009	Jaykara Jaykaran
+	Surrogate end points: hopes and perils	2008	Ariel Alonso Geert Molenberghs
+ PDF Chat	Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging	2018	Lesley A. Inker Hiddo J.L. Heerspink
+	Surrogate Markers	2015	Geert Molenberghs
+	Surrogate Endpoints in Clinical Trials	1996	Thomas R. Fleming
+	Surrogate endpoints in clinical trials	1985	Lawrence Friedman Salim Yusuf
+ PDF Chat	Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes	2014	Stuart G. Baker Barnett S. Kramer
+	Surrogate outcomes	2016	Cătălin Tufănaru
+	Biomarkers and Surrogates in Clinical Studies	2008	Claudio Rigatto Brendan J. Barrett
+ PDF Chat	Criteria for Scientific Evaluation of Novel Markers: A Perspective	2010	Karel G.M. Moons
+ PDF Chat	Significance of biomarkers and surrogate endpoints in preclinical and clinical trials	2007	Katarina Ilić Vesna Kuntić
+ PDF Chat	Debate: The slippery slope of surrogate outcomes	2000	Ralph B. D’Agostino

Works That Cite This (11)

Action	Title	Year	Authors
+	SURROGATES FOR QUALITATIVE EVALUATION OF TREATMENT EFFECTS	2015	Zhi Geng
+	Novel Criteria to Exclude the Surrogate Paradox and Their Optimalities	2016	Yunjian Yin Lan Liu Zhi Geng Peng Luo
+ PDF Chat	Novel criteria to exclude the surrogate paradox and their optimalities	2019	Yunjian Yin Lan Liu Zhi Geng Peng Luo
+	Methodische Anforderungen an klinische Studien und ihre Interpretation	2009	Jürgen Windeler Stefan Lange
+	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials	2009	Qian Shi Daniel J. Sargent
+	Evaluation of Causal Effects and Local Structure Learning of Causal Networks	2018	Zhi Geng Yue Liu Chunchen Liu Wang Miao
+ PDF Chat	Sharp bounds on causal effects using a surrogate endpoint	2013	Manabu Kuroki
+	Criteria for Surrogate end Points Based on Causal Distributions	2010	Chuan Ju Zhi Geng
+	Sufficient conditions for concluding surrogacy based on observed data	2011	Zhenguo Wu Ping He Zhi Geng
+	Statistical Considerations for the Next Generation of Clinical Trials	2011	Wenting Wu Qian Shi Daniel J. Sargent

Works Cited by This (11)

Action	Title	Year	Authors
+	Evaluating surrogate endpoints	2002	Michael D. Hughes
+	Surrogate markers and joint models for longitudinal and survival data	2002	Jeremy M. G. Taylor Yan Wang
+	The Cardiac Arrhythmia Suppression Trial	1995	Craig M. Pratt Lemuel A. Moyé
+ PDF Chat	Surrogate end points in clinical trials.	1991	S S Ellenberg
+	Surrogate End Points in Clinical Trials: Are We Being Misled?	1996	Thomas R. Fleming
+	The Evaluation of Surrogate Endpoints	2006	Hans C. van Houwelingen
+ PDF Chat	Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease	1999	Bruce M. Psaty
+	ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER	1997	D. Y. Lin Thomas R. Fleming Victor De Gruttola
+	Proportion of treatment effect (PTE) explained by a surrogate marker	2003	Cong Chen Hongwei Wang Steven Snapinn
+	Surrogate endpoints in clinical trials: Definition and operational criteria	1989	Ross L. Prentice